The CBX5 Knockout Huh-7 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from Huh-7 human hepatocellular carcinoma cells, engineered for disruption of the CBX5 gene. This loss-of-function model enables investigation of HP1??-dependent heterochromatin biology in a liver cancer context without introducing a single clonal bias. The polyclonal format captures a spectrum of editing events, providing a heterogeneous pool that better reflects the diversity of genetic perturbations and is suitable for bulk functional genomic studies.
The Huh-7 host cell line is a widely used human hepatocellular carcinoma model established from a liver tumor. It retains key hepatocyte features, including expression of liver-specific functions and permissiveness to hepatitis C virus (HCV) replication, making it valuable for studying liver cell biology, hepatocarcinogenesis, and host-pathogen interactions. The highly tumorigenic nature of Huh-7 cells offers a robust platform for examining oncogenic mechanisms and therapeutic interventions relevant to liver cancer.
CBX5 encodes the chromobox homolog 5 (HP1??), a core component of constitutive heterochromatin. HP1?? specifically binds trimethylated histone H3 at lysine 9 (H3K9me3) and interacts with factors such as SUV39H1, SETDB1, Lamin B receptor, and HDAC1/2 to maintain repressive chromatin states. It functions downstream of E2F1, p53, and ATM/ATR kinases, and regulates downstream effectors including p21 (CDKN1A) and p14ARF. Through these interactions, CBX5 governs heterochromatin integrity, DNA damage response, and p53-dependent senescence pathways.
Disruption of CBX5 in Huh-7 cells abrogates HP1??-mediated heterochromatin formation, resulting in de-repression of silenced genomic loci and global transcriptional changes. This perturbation is predicted to compromise genome stability, activate latent DNA damage signaling, and potentially induce premature senescence in a p53-competent background. The model allows dissection of how heterochromatin loss impacts hepatocellular carcinoma progression, providing insight into epigenetic dysregulation in liver tumors.
This knockout cell population is suited for a range of experimental applications, including chromatin immunoprecipitation (ChIP)-qPCR to assess H3K9me3 and CBX5 occupancy, RT-qPCR and RNA-seq to profile de-repressed genes, and immunofluorescence to visualize heterochromatin foci. Functional assays such as cell proliferation, senescence-associated ??-galactosidase staining, and ??H2AX foci analysis enable evaluation of tumor-suppressive mechanisms. It also supports drug target validation for chromatin modifiers and investigation of HCV latency reactivation. For additional technical details or ordering information, please contact Ascent Research.
